Afib Ablation Exceeds Expectations in Sickest Heart Failure Patients
AMSTERDAM — Catheter ablation conferred large clinical benefits to people with end-stage heart failure and symptomatic atrial fibrillation (Afib) in the small CASTLE HTx randomized trial that was terminated prematurely for efficacy. The trial, originally planned for 2 years, was brought to a halt upon the discovery that these patients undergoing catheter ablation had fewer […]
Opinion | Who Is to Blame for the Rampant Overtreatment of Peripheral Artery Disease?
Hicks is an associate professor of surgery and a director of clinical outcomes research. The recent New York Times article highlighting inappropriate treatment patterns among patients with peripheral artery disease (PAD) has made a serious but much needed impact on patients and physicians alike. The article is complemented by a series of ProPublica articles that […]
Cognitive Dysfunction, Viral Persistence Studied First in New Long COVID Trials
The first two of the long-awaited long COVID clinical trials from the RECOVER initiative are underway, the NIH said. RECOVER-NEURO, which will study interventions for long COVID cognitive dysfunction, and RECOVER-VITAL, a study targeting viral persistence, are opening enrollment, said Acting NIH Director Lawrence Tabak, DDS, PhD, in a press briefing today. Two other trials, […]
Donanemab Slows Progression in Early Alzheimer’s
AMSTERDAM — Investigational donanemab significantly slowed clinical progression at 76 weeks in people with early symptomatic Alzheimer’s disease who had amyloid and tau pathology, the phase III TRAILBLAZER-ALZ 2 trial showed. The drug, which targets a modified form of beta amyloid known as N3pG, showed significant slowing versus placebo on measures of cognition and daily […]
Testing PD-1 Inhibition With Neoadjuvant Anti-HER2 Therapy in Breast Cancer
At the American Society of Clinical Oncology (ASCO) annual meeting, researchers reported on a multicenter, phase II trial exploring the efficacy and safety of adding pembrolizumab (Keytruda) to the standard-of-care treatment of paclitaxel (Taxol), trastuzumab (Herceptin), and pertuzumab (Perjeta; THP) in chemotherapy-naive patients with invasive, HER2-positive breast cancer. In this exclusive MedPage Today video, Jin […]
Topical Therapies for Adult Atopic Dermatitis
Next Article Key Points “Medical Journeys” is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state contains both a physician guide and a downloadable/printable patient resource. “Medical Journeys” chart a path each step of […]
PD-1 Inhibition in First-Line Prolongs Survival in Cervical Cancer
Updated findings of KEYNOTE-826, presented at the American Society of Clinical Oncology (ASCO) annual meeting, continued to demonstrate a significant survival benefit with the addition of pembrolizumab (Keytruda) to standard treatment for previously untreated recurrent or metastatic cervical cancer. In this exclusive MedPage Today video, Deanna Gerber, MD, of the NYU Long Island School of […]
Mirikizumab Benefit in UC Extends Into Maintenance Phase
The investigational monoclonal antibody mirikizumab was more effective in inducing and maintaining clinical remission in patients with moderate to severe ulcerative colitis (UC) compared with placebo, according to two phase III randomized trials. Among over 1,200 patients in the LUCENT-1 induction trial, 24.2% of those who received mirikizumab experienced clinical remission at week 12 compared […]
New Antiviral Option for CMV Prophylaxis After Kidney Transplant
Letermovir (Prevymis) proved noninferior to valganciclovir (Valcyte), the standard of care, in a clinical trial of cytomegalovirus (CMV) prophylaxis in high-risk kidney transplant patients, researchers reported. In a phase III trial of 589 patients randomized 1:1 to receive either drug for up to 200 days post-transplant, the prevalence of CMV disease at 1 year was […]
Cardiorespiratory Monitoring Can Be Telling of Outcomes in Extremely Preterm Infants
Physiologic data from cardiorespiratory monitoring may provide prognostic information about the clinical outcomes of extremely preterm infants, the Prematurity-Related Ventilatory Control (Pre-Vent) study found. The endpoint of death or need for respiratory medications or support at 40 weeks postmenstrual age (PMA) was predicted by physiological parameters, the relationship growing stronger as the babies got older, […]